Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention as a tool ...

Lenacapavir, trialed in Uganda, offers 100% protection but will it reach those who need it most? Kampala, Uganda | RONALD ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

A landmark breakthrough in HIV prevention received final approval from the Food and Drug Administration last month. Gilead Sciences’ lenacapavir is so effective that global health leaders had started ...

Even more concerning? The loss of data. The US funded most HIV tracking systems in Africa, and many have now stopped collecting patient and hospital records.

Brian Hodous, Ph.D., promoted to chief scientific officer-- Vivek Kadambi, Ph.D., joins Recludix as senior vice president of non-clinical scienc ...

DAR ES SALAAM: INDIA’s Haryana State Electronics Development Corporation (HARTRON) is setting its sights on Tanzania’s ...